Speakers

Dr Partha Basu, International Agency for Research on Cancer, France

Dr. Partha Basu joined the Screening Group of the International Agency for Research on Cancer (IARC) in March 2015. He practiced Gynecological Oncology for 20 years and was the Head of the Department of Gynecological Oncology at Chittaranjan National Cancer Institute, India before joining IARC. Dr. Basu obtained his MD in Obstetrics & Gynecology from Indira Gandhi Medical College, India and post-graduate fellowship in Gynecological Oncology from Imperial College, London. He is a PhD in Clinical Oncology from West Bengal University of Health Sciences, India. Dr. Basu’s research areas include evaluation of new strategies for control of non-communicable diseases, reporting performance of cancer screening programs in different countries, assessment of novel treatment methods for cervical precancers, evaluating less than three doses of HPV vaccine, evaluation of CBE and ultrasound as alternative breast cancer screening tests, implementation and evaluation of pilot colorectal cancer screening programs etc. Dr. Basu has 82 publications in international peer reviewed journals and has authored 20 books/book chapters. He has contributed to several WHO guidelines and served as consultant to the Ministries of Health in India and several South Asian countries and also to United Nations Population Fund (UNFPA).

Ms Tamzin Cuming, Homerton University Hospital, UK

Tamzin Cuming is a colorectal consultant surgeon at Homerton Anogenital Neoplasia Service (HANS) where she specialises in high resolution anoscopy (HRA) and laser ablation of lower anogenital tract high grade intraepithelial neoplasia. She qualified in 1994 from Guy’s and St Thomas’s Hospitals after a first degree at Cambridge and obtained the FRCS (England) in 1998. She had three children during training in surgery and completed training with the exit FRCS (General Surgery, 2010) and a Masters in surgical Education at Imperial (2012). On taking up her consultant post at Homerton in 2013, she began training in High resolution anoscopy under Dr Mayura Nathan, a world expert in HRA. She took over the directorship of the HANS unit from him in 2018 on his retirement.

Professor Alison Fiander, RCOG, UK

In 2002 Alison was appointed Chair of Obstetrics and Gynaecology and Head of Department to University of Wales College of Medicine (UWCM), subsequently becoming the School of Medicine, Cardiff University. She established an HPV research laboratory and appointed a multidisciplinary scientific and clinical HPV research team investigating the epidemiology, basic and translational science and psychosocial aspects of HPV infection. This included the epidemiology of HPV infection in Wales; the investigation of prognostic biomarkers for HPV infection; biomarkers of treatment response; prophylactic HPV vaccination and novel management of anogenital neoplasia. She continued to develop a tertiary referral practice for patients with anogenital intraepithelial neoplasia, establishing a multidisciplinary surgical team comprising gynaecology, colorectal and reconstructive surgery to manage extensive multifocal, multicentric anogenital neoplastic disease. Alison has a passion for Women's Health in low resourced countries (LRC) especially sub-Saharan Africa. Immediately after passing specialist exams in obstetrics and gynaecology she worked in Northern Ghana for two years in a district general hospital on the border with Togo and Burkina Faso. She has acted as external examiner for both undergraduates and specialist trainees in Obstetrics and Gynaecology for Kilimanjaro Christian Medical College, Tanzania and helped to establish a study of HPV infection and cervical neoplasia in The Gambia. In 2010 she applied for a two-year career break to undertake training and subsequent practice in repair of obstetric fistulae in Sierra Leone and Tanzania, returning in September 2012. During her time in Tanzania she published papers on obstetric fistula and helped establish a 'holistic care' programme for women undergoing fistula repair at a large disability hospital in Dar es Salaam, Tanzania. Keen to work further in Global Women’s Health Alison was appointed Clinical Lead to the RCOG’s ‘Leading Safe Choices’ programme in 2015. Leading Safe Choices aims to improve sexual reproductive health in South Africa and Tanzania by training and mentoring health care professionals in ‘Best Practice’. She was subsequently appointed Clinical Lead to the RCOG Centre for Women’s Global Health and has overseen the development of a training package for low resource settings in ‘Essential Gynaecology Skills’, including a module on the prevention, diagnosis, management and palliation of cervical cancer. Alison is well aware of the devastating impact of cervical cancer on women’s physical, psychosocial and sexual wellbeing from both UK and clinical practice in LRCs.

Dr Emma King, Poole Hospital NHS Foundation Trust, UK

Emma King is a Consultant Head and Neck Surgeon at Poole Hospital NHS Foundation Trust. She is also an Associate Professor of Head and Neck surgery at the University of Southampton. Her PhD was in mucosal immunology at the University of Bristol. Her specialist Otorhinolaryngology training was in Wessex, before undertaking a 2 year ablative and reconstructive head and neck surgical oncology fellowship at the Princess Margaret Hospital in Toronto. In Southampton she works within a translational immunotherapy group who design early phase immunotherapy trials to understand which patients benefit from immunotherapy agents and how to convert those non-responders into responders.

Professor Peter Sasieni, King’s College London, UK

Professor Peter Sasieni is an epidemiologist with 25 years’ experience in cervical cancer screening research. He is currently Professor of Cancer Prevention in the School of Cancer & Pharmaceutical Sciences at King’s College London and Director of the King’s Clinical Trials Unit. Professor Sasieni’s research includes both methodological issues related to the design and analysis of clinical trials and epidemiological studies, as well as clinical studies of cancer screening and chemoprevention with a particular interest in cervix cancer. He has a Cancer Research UK programme grant to study “Cancer Screening and Statistics”, is Director of their Cancer Prevention Trials Unit (based at Barts) and Vice Director of the Department of Health’s Policy Research Unit in Cancer Awareness, Screening and Early Diagnosis. He sits on a number of advisory committees (including the Advisory Committee on Cervical Screening in England) and grant award committees.